These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38508074)

  • 21. Comparison of the efficacy and safety of 10 glucagon-like peptide-1 receptor agonists as add-on to metformin in patients with type 2 diabetes: a systematic review.
    Xie Z; Hu J; Gu H; Li M; Chen J
    Front Endocrinol (Lausanne); 2023; 14():1244432. PubMed ID: 37701904
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction.
    Nauck MA; D'Alessio DA
    Cardiovasc Diabetol; 2022 Sep; 21(1):169. PubMed ID: 36050763
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Model-based simulation of glycaemic effect and body weight loss when switching from semaglutide or dulaglutide to once weekly tirzepatide.
    Urva S; Levine JA; Schneck K; Tang CC
    Curr Med Res Opin; 2024 Apr; 40(4):567-574. PubMed ID: 38407177
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synchronous spectrofluorimetric determination of favipiravir and aspirin at the nano-gram scale in spiked human plasma; greenness evaluation.
    Batubara AS; Ainousah BE; Ramzy S; Abdelazim AH; Gamal M; Tony RM
    Spectrochim Acta A Mol Biomol Spectrosc; 2023 Oct; 299():122880. PubMed ID: 37216820
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The impact of tirzepatide and glucagon-like peptide 1 receptor agonists on oral hormonal contraception.
    Skelley JW; Swearengin K; York AL; Glover LH
    J Am Pharm Assoc (2003); 2024; 64(1):204-211.e4. PubMed ID: 37940101
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Green and sensitive spectrofluorimetric determination of Remdesivir, an FDA approved SARS-CoV-2 candidate antiviral; application in pharmaceutical dosage forms and spiked human plasma.
    Elmansi H; Ibrahim AE; Mikhail IE; Belal F
    Anal Methods; 2021 Jun; 13(23):2596-2602. PubMed ID: 34019051
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide.
    Schneck K; Urva S
    CPT Pharmacometrics Syst Pharmacol; 2024 Mar; 13(3):494-503. PubMed ID: 38356317
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In type 2 diabetes, tirzepatide reduced HbA
    Gandhi GY
    Ann Intern Med; 2021 Nov; 174(11):JC127. PubMed ID: 34724396
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Short-term cost-effectiveness analysis of tirzepatide for the treatment of type 2 diabetes in the United States.
    Zhang X; McAdam Marx C
    J Manag Care Spec Pharm; 2023 Mar; 29(3):276-284. PubMed ID: 36840958
    [No Abstract]   [Full Text] [Related]  

  • 30. Effect of the Dual Glucose‐Dependent Insulinotropic Peptide/Gulcagon‐like Peptide 1 Receptor Agonist Tirzepatide on Lipid Profile and Waist Circumference: A Systematic Review and Meta‐analysis.
    Yu D; Shen S; Zhang J; Wang Q
    Clin Ther; 2023 Aug; 45(8):787-796. PubMed ID: 37455226
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tirzepatide in Hispanic/Latino Patients With Type 2 Diabetes: A Subgroup Analysis of the SURPASS Program.
    Frías JP; Galindo RJ; Wang H; Malik RE; Chivukula KK; Maldonado JM
    J Clin Endocrinol Metab; 2024 Jan; 109(2):557-568. PubMed ID: 37602701
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Add-on value of tirzepatide versus semaglutide.
    Scheen AJ
    Lancet Diabetes Endocrinol; 2022 Jun; 10(6):377-378. PubMed ID: 35468323
    [No Abstract]   [Full Text] [Related]  

  • 33. Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes.
    Santulli G
    N Engl J Med; 2022 Feb; 386(7):e17. PubMed ID: 35172066
    [No Abstract]   [Full Text] [Related]  

  • 34. Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes.
    Patoulias D; Papadopoulos C; Doumas M
    N Engl J Med; 2022 Feb; 386(7):e17. PubMed ID: 35172065
    [No Abstract]   [Full Text] [Related]  

  • 35. Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes. Reply.
    Frías JP; Fernández Landó L; Brown K
    N Engl J Med; 2022 Feb; 386(7):e17. PubMed ID: 35172067
    [No Abstract]   [Full Text] [Related]  

  • 36. Effect of tirzepatide on albuminuria levels and renal function in patients with type 2 diabetes mellitus: A systematic review and multilevel meta-analysis.
    Karakasis P; Patoulias D; Fragakis N; Klisic A; Rizzo M
    Diabetes Obes Metab; 2024 Mar; 26(3):1090-1104. PubMed ID: 38116693
    [TBL] [Abstract][Full Text] [Related]  

  • 37. At ObesityWeek, More Data and Questions About Semaglutide, Tirzepatide, and Retatrutide.
    Ruder K
    JAMA; 2024 Jan; 331(1):9-11. PubMed ID: 38055301
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [A new era for glucagon-like peptide-1 receptor agonists].
    Neuville MF; Paquot N; Scheen AJ
    Rev Med Liege; 2023 Jan; 78(1):40-45. PubMed ID: 36634066
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tirzepatide, the Newest Medication for Type 2 Diabetes: A Review of the Literature and Implications for Clinical Practice.
    Bradley CL; McMillin SM; Hwang AY; Sherrill CH
    Ann Pharmacother; 2023 Jul; 57(7):822-836. PubMed ID: 36367094
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tirzepatide: a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) dual agonist in development for the treatment of type 2 diabetes.
    Frías JP
    Expert Rev Endocrinol Metab; 2020 Nov; 15(6):379-394. PubMed ID: 33030356
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.